Prognostic role of perineural invasion in prostate biopsy

Gutiérrez, C.; Terrasa, F.; Briones, G.; Santos, G. Conde; Fuentes, Inma; Hidalgo, F.; Bestard, Joan Perelló; Rebassa, M.

doi:10.1016/j.acuroe.2011.01.002

Cited by 3 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bu yüzden prostat biyopsi patolojisindeki PNİ bulgusunun ekstraprostatik yayılımda önemli bir bulgu olabileceği saptanmıştır (15). Yapılan çalışmalarda prostat biyopsisindeki PNİ pozitifliği ile ekstraprostatik yayılım, cerrahi sınır ve lenf nodu pozitifliği araştırılmış ve anlamlı sonuçlar saptanmıştır (7,8,9 …”

Section: Discussionunclassified

“…Prostat biyopsilerinde prostat kanser hücrelerinin sinir demeti boyunca yayılımını gösteren perinöral invazyon (PNİ) bulgusu biyopsi patolojilerinde rutin olarak raporlanmaktadır (6). PNİ varlığının ekstraprostatik yayılım ve cerrahi sınır pozitifliği ile ilişkili olduğu bazı çalışmalarda gösterilmiştir (7,8,9). Bu çalışmada RRP materyalinde pT3 prostat kanseri saptanan hastaların prostat biyopsisindeki PNİ bulgularının ekstraprostatik yayılımın derecesi ve seminal vezikül invazyonu ile olan ilişkisini değerlendirmeyi amaçladık.…”

Section: Introductionunclassified

See 1 more Smart Citation

Clinical Significance of Perineural Invasion in Prostate Needle Biopsy in Patients Diagnosed with Extraprostatic Extension and Seminal Vesicle Invasion after Radical Prostatectomy

Bozkurt¹,

Çelik²,

Demir³

et al. 2015

uob

View full text Add to dashboard Cite

Section: Discussionunclassified

Section: Introductionunclassified

Clinical Significance of Perineural Invasion in Prostate Needle Biopsy in Patients Diagnosed with Extraprostatic Extension and Seminal Vesicle Invasion after Radical Prostatectomy

Bozkurt¹,

Çelik²,

Demir³

et al. 2015

uob

View full text Add to dashboard Cite

“…Similarly, in the current study, GS ≤6 was shown to be the most important independent predictive factor for this prediction (OR: 24.537). Additionally, PNI on biopsy and extraprostatic extension and surgical margin positivity after RP were shown to be highly correlated [21][22][23][24][25][26]. However, PNI on biopsy was not always an independent predictive factor of sPCa [27,28].…”

Section: Discussionmentioning

confidence: 92%

Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey

et al. 2021

View full text Add to dashboard Cite

Background: Epstein criteria based on sextant biopsy are assumed to be valid for 12-core biopsies. However, very scarce information is present in the current literature to support this view. Objectives: To investigate the validity of Epstein criteria for clinically insignificant prostate cancer (PCa) in a cohort of the currently utilized 12-core prostate biopsy (TRUS-Bx) scheme in patients with low-risk and intermediate-risk PCa. Method: Pathological findings were separately evaluated in the areas matching the sextant biopsy (6-core paramedian) scheme and in all 12-core schemes. Patients were divided into 2 groups according to the final pathology report of RP as true clinically significant PCa (sPCa) and insignificant PCa (insPCa) groups. Predictive factors (including Epstein criteria) and cutoff values for the presence of insPCa were separately evaluated for 6- and 12-core TRUS-Bx schemes. Then, different predictive models based on Epstein criteria with or without additional biopsy findings were created. Results: A total of 442 patients were evaluated. PSA density, biopsy GS, percentage of tumor and number of positive cores, PNI, and HG-PIN were independent predictive factors for insPCa in both TRUS-Bx schemes. For the 12-core scheme, the best cutoff values of tumor percentage and number of positive cores were found to be ≤50% (OR: 3.662) and 1.5 cores (OR: 2.194), respectively. The best predictive model was found to be that which added 3 additional factors (PNI and HG-PIN absence and number of positive cores) to Epstein criteria (OR: 6.041). Conclusions: Using a cutoff value of “1” for the number of positive biopsy cores and absence of biopsy PNI and HG-PIN findings can be more useful for improving the prediction model of the Epstein criteria in the 12-core biopsy scheme.

show abstract

“…The same findings in our study were identified in the PNI positive patient group (p < 0.01). Studies about prediction of local invasion (T3 disease, extraprostatic extension, lymph node positivity) have identified significant results between presence of PNI on PNB and local invasion findings and surgical margin positivity [7,11,12]. A meta‐analysis concluded that PNB PNI positivity was a significant marker to predict T3 disease and may be included in new nomograms [18].…”

Section: Discussionmentioning

confidence: 99%

“…The presence of PNI is generally accompanied by high Gleason score (GS) and high prostate specific antigen (PSA) rates [7]. Additionally, some studies have shown a correlation between PNI presence and extraprostatic extension and surgical margin positivity [7,11,12]. However, PNI presence has not been included as a parameter in any studies predicting local invasion.…”

Section: Introductionmentioning

confidence: 99%

Effects of perineural invasion in prostate needle biopsy on tumor grade and biochemical recurrence rates after radical prostatectomy

Çelik

Bozkurt

Demir

et al. 2018

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

To predict local invasive disease before retropubic radical prostatectomy (RRP), the correlation of perineural invasion (PNI) on prostate needle biopsy (PNB) and RRP pathology data and the effect of PNI on biochemical recurrence (BR) were researched. For patients with RRP performed between 2005 and 2014, predictive and pathologic prognostic factors were assessed. Initially all and D'Amico intermediate-risk group patients were comparatively assessed in terms of being T2 or T3 stage on RRP pathology, positive or negative for PNI presence on PNB and positive or negative BR situation. Additionally the effect of PNI presence on recurrence-free survival (RFS) rate was investigated. When all patients are investigated, multivariate analysis observed that in T3 patients PSA, PNB Gleason score (GS) and tumor percentage were significantly higher; in PNI positive patients PNB GS, core number and tumor percentage were significantly higher and in BR positive patients PNB PNI positivity and core number were significantly higher compared to T2, PNI negative and BR negative patients, separately (p < 0.05). When D'Amico intermediate-risk patients are evaluated, for T3 patients PSA and PNB tumor percentage; for PNI positive patients PNB core number and tumor percentage; and for BR positive patients PNB PNI positivity were significantly higher compared to T2, PNI negative and BR negative patients, separately (p < 0.05). Mean RFS in the whole patient group was 56.4 ± 4.2 months for PNI positive and 96.1 ± 5.7 months for negative groups. In the intermediate-risk group, mean RFS was 53.7 ± 5.1 months for PNI positive and 100.3 ± 7.7 months for negative groups (p < 0.001). PNI positivity on PNB was shown to be an important predictive factor for increased T3 disease and BR rates and reduced RFS.

show abstract

Prognostic role of perineural invasion in prostate biopsy

Cited by 3 publications

References 31 publications

Clinical Significance of Perineural Invasion in Prostate Needle Biopsy in Patients Diagnosed with Extraprostatic Extension and Seminal Vesicle Invasion after Radical Prostatectomy

Clinical Significance of Perineural Invasion in Prostate Needle Biopsy in Patients Diagnosed with Extraprostatic Extension and Seminal Vesicle Invasion after Radical Prostatectomy

Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey

Effects of perineural invasion in prostate needle biopsy on tumor grade and biochemical recurrence rates after radical prostatectomy

Contact Info

Product

Resources

About